Nuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer

Aug. 15, 2022 13:00 UTC


Physician-scientist and biopharmaceutical executive with extensive experience in novel drug development and pipeline strategy


REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Nuvig Therapeutics, Inc. a private biotech company developing novel therapeutics to restore immune homeostasis and treat chronic autoimmune diseases, announced today the appointment of Joanne Quan, M.D., as Chief Medical Officer. Dr. Quan has more than 25 years of experience advancing novel drug candidates in all stages of development, from preclinical compounds to marketed products.

“Joanne has a passion and commitment to developing new therapies for patients with high unmet medical needs and has a successful track record in advancing novel drug candidates for a wide range of therapeutic areas, including autoimmune disorders and rare and orphan diseases,” said Pamela Conley, Ph.D., Chief Executive Officer and Cofounder of Nuvig Therapeutics. “In addition, Joanne has built nimble and creative teams and has led multiple successful collaborations and partnerships to support the progression of new therapies to commercialization.”

Dr. Quan added, “What attracted me to Nuvig was the incredible science and the potential to develop therapies for multiple immunologic diseases, many of which have few or no treatment options. It’s exciting to join Nuvig at this stage as we refine the scientific and clinical strategy and build the company to maximize the reach of this novel approach. I look forward to demonstrating proof-of-concept as we move into the clinic.”

Prior to Nuvig, Dr. Quan was Chief Medical Officer at Modis Therapeutics, a company focused on developing disease-modifying therapies for patients with rare genetic diseases. After Modis was acquired by Zogenix, Dr. Quan, as a member of the Executive Team, continued to lead drug development for mitochondrial diseases, including advancing nucleoside therapy for thymidine kinase 2 deficiency toward filing in U.S. and Europe. Before Modis, she held positions of increasing responsibility at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson and Johnson), Genentech, and PathoGenesis. Dr. Quan received a B.A. in molecular biology at the University of California, Berkeley and an M.D. at Stanford University School of Medicine. She completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Pulmonary and Critical Care Medicine at the University of Washington.

About Nuvig Therapeutics

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and provide better treatments for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases. For more info, visit


Corporate: Pamela Conley, Ph.D., CEO, Nuvig Therapeutics, Inc.,
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc.,, +1.858.344.8091


Source: Nuvig Therapeutics, Inc.

Back to news